All News
Filter News
Found 9,485 articles
-
SonoThera™ Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development
12/5/2022
Lead investor ARCH Venture Partners is joined by Illumina Ventures, Johnson & Johnson Innovation – JJDC, Inc., Vertex Ventures HC, Medical Excellence Capital and others in global biotechnology and pharmaceutical investment.
-
Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results
12/5/2022
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced financial results for its fiscal 2022 fourth quarter and full year ended September 30, 2022 and provided a business update.
-
Quanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
12/5/2022
Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa® technology has powered important advances in ongoing clinical trials for the treatment of Alzheimer’s disease (AD).
-
SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph.D., as Chief Scientific Officer, and Provides Update on Pipeline of Novel CNS Therapeutics
12/2/2022
SciNeuro Pharmaceuticals is developing novel therapeutics to address major unmet need within CNS diseases. The company is pleased to announce an executive leadership appointment, and update on key pipeline progress milestones.
-
High Potency Active Pharmaceutical Ingredients Market Size, Share, Growth, Trends, Forecast 2021 to 2030
12/2/2022
The global high potency active pharmaceutical ingredients market size is expected to be worth around US$ 44.8 billion by 2030, according to a new report by Vision Research Reports.
-
Omics-based Clinical Trials Market Size to Reach Around US$ 50.5 BN by 2030
12/2/2022
According to Research Report Study, the global omics-based clinical trials market size was valued at USD 25.2 billion in 2020, and is predicted to be worth around USD 50.5 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.
-
Eli Lilly’s investigational antibody donanemab met all of its primary and secondary endpoints in the Phase III TRAILBLAZER-ALZ 4 study, the company announced Wednesday.
-
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
12/1/2022
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS).
-
ADDF Statement on Gantenerumab Data Presented at CTAD
12/1/2022
The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease conference demonstrate why optimal treatment of Alzheimer's will require drugs that do more than clear amyloid plaques.
-
Nimbus reported positive Phase IIb results for NDI-034858 in moderate-to-severe plaque psoriasis, which researchers hope will have the efficacy of JAK inhibitors without the safety issues.
-
Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
11/30/2022
Eli Lilly and Company (NYSE: LLY) has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase 3 TRAILBLAZER-ALZ 4 study, providing the first active comparator data on amyloid plaque clearance in patients with early symptomatic Alzheimer's disease treated with amyloid-targeting therapies.
-
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
11/30/2022
AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that based on the Phase 1b/2a interim data, ACI-35.030, a potential first-in-class anti-phosphorylated-Tau (pTau) vaccine candidate, has been selected for further development.
-
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
11/30/2022
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pierre Fabre for the BRAF inhibitor encorafenib (BRAFTOVI®) within key international territories.
-
Lilly and Akouos Announce Expiration of Akouos Tender Offer
11/30/2022
Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share.
-
Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement
11/29/2022
Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2023 on Tuesday, Dec. 13, 2022.
-
Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings
11/28/2022
Innovent Biologics, Inc. announced that clinical data from multiple trials in relation to TYVYT®, olverembatinib, IBI188, IBI110 and IBI939 will be presented at the upcoming international medical conferences.
-
Strand Therapeutics Announces Series A1 Bringing Total Round to US$97 Million
11/28/2022
Strand Therapeutics , the programmable mRNA company developing curative therapies for cancer and other diseases, today announced it has added an additional $45M to its Series A financing round, bringing the total amount raised in the Series A to $97 million.
-
Veru to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on December 5, 2022
11/28/2022
Veru Inc. (NASDAQ: VERU) today announced it will host a conference call and audio webcast on Monday, December 5, 2022, at 8:00 a.m. ET to discuss its fiscal 2022 fourth quarter and full year ended September 30, 2022 financial results and provide a business update.
-
Personalized Medicine Biomarkers Market Size, Share | Report 2022-2030
11/28/2022
The growth of the personalized medicine biomarkers market is attributed to increasing demand and growing awareness about personalized medicine among healthcare professionals.
-
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements - November 23, 2022
11/23/2022
BeyondSpring Inc. announced that on November 18, 2022, it received a written notification from The Nasdaq Stock Market LLC that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550, because the closing bid price of the Company’s ordinary shares was below $1.00 per share for 30 consecutive business days.